AVAFY Trademark

Trademark Overview

On Tuesday, June 18, 2019, a trademark application was filed for AVAFY with the United States Patent and Trademark Office. The USPTO has given the AVAFY trademark a serial number of 88478425. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Thursday, July 2, 2020. This trademark is owned by Flamel Ireland Limited. The AVAFY trademark is filed in the Pharmaceutical Products category with the following description:

parenterally-administered pharmaceuticals for treatment of cysteine-deficient newborns and infants; pharmaceuticals for treatment of cysteine-deficient newborns and infants; pharmaceuticals for treatment of cysteine deficiencies
avafy

General Information

Serial Number88478425
Word MarkAVAFY
Filing DateTuesday, June 18, 2019
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateThursday, July 2, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 1, 2019

Trademark Statements

Goods and Servicesparenterally-administered pharmaceuticals for treatment of cysteine-deficient newborns and infants; pharmaceuticals for treatment of cysteine-deficient newborns and infants; pharmaceuticals for treatment of cysteine deficiencies

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateThursday, July 2, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAVADEL LEGACY PHARMACEUTICALS, LLC
Party Type21 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressCHESTERFIELD, MO 63005
Party NameFlamel Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBallycoolin Dublin 15
IE
Party NameFlamel Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBallycoolin Dublin 15
IE

Trademark Events

Event DateEvent Description
Thursday, July 2, 2020ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Wednesday, July 1, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, July 1, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 1, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 1, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 1, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, July 2, 2020ABANDONMENT - AFTER PUBLICATION
Wednesday, July 1, 2020TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, June 30, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, June 30, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, June 30, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, June 30, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, June 30, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, April 29, 2020AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, April 24, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 22, 2020EXTENSION 1 GRANTED
Wednesday, April 22, 2020EXTENSION 1 FILED
Wednesday, April 22, 2020TEAS EXTENSION RECEIVED
Tuesday, November 26, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 1, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 1, 2019PUBLISHED FOR OPPOSITION
Wednesday, September 11, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, August 23, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 23, 2019ASSIGNED TO EXAMINER
Friday, June 28, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, June 21, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

avafy treatment pharmaceuticals cysteine infants newborns deficient deficiencies parenterally administered